Twenty U.S. states including California, Connecticut and Michigan have pushed back against a $10 million settlement that Florida reached with Swiss generic drugmaker Sandoz, saying a key provision ...

Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturerAgreement will secure a reliable ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

Sandoz garners chunky demand for 10 year trade ◆ Trend continues for issuers to set deal parameters quickly ◆ Single digit ...

Sandoz last year agreed to pay $265 million to resolve related claims lodged in the litigation by a group of wholesale drug purchasers and others. The case is In re Generic Pharmaceuticals Pricing ...

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion). The Sandoz Family Foundation, through the vehicle Emasan AG ...

Skincare product maker Galderma, and pharmaceutical company Sandoz both returned to their home market this week, bringing ...

Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturer Agreement will secure a reliable supply of affordable, quality sterile injectables ...

For Europe, it is still too early to model,” Sandoz CEO Richard Saynor said in a statement to Pharmaceutical Technology. Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US ...